Cipla Limited has informed the Exchange about Transcript
CIPLA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Cipla submitted the transcript of its Q4 FY25 earnings call held on May 13, 2025. For the full year, revenue grew 8% YoY to INR 27,548 crores, with Q4 revenue at INR 6,730 crores (up 9% YoY). Full year EBITDA margin came in at 25.9%, exceeding the company's earlier guidance. PAT for the year stood at INR 5,273 crores, with ROIC above 30% and a strong net cash position of INR 10,369 crores. The One India business crossed INR 11,000 crores in revenue, and Foracort became the first brand in IPM history to cross INR 900 crores. North America posted an annual revenue of $934 million with two key approvals (nano paclitaxel ANDA and Nilotinib NDA). Africa and EMEU businesses delivered strong double-digit growth.
Management guided FY26 EBITDA margin to a lower range of 23.5%–24.5%, citing the loss of exclusivity for generic Revlimid in the US and a change in product mix, which signals near-term margin pressure despite continued revenue growth momentum.